

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version  
6.1

Revision Date:  
13.11.2025

SDS Number:  
20448-00027

Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Raltegravir Pediatric Granules Formulation

#### Manufacturer or supplier's details

Company : MSD

Address : Briahnager - Off Pune Nagar Road  
Wagholi - Pune - India 412 207

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

### 2. HAZARDS IDENTIFICATION

#### Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

##### Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

##### GHS Classification

Serious eye damage/eye irritation : Category 1

Reproductive toxicity : Category 2

Specific target organ toxicity - single exposure : Category 3

Short-term (acute) aquatic hazard : Category 3

##### GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H318 Causes serious eye damage.

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version  
6.1

Revision Date:  
13.11.2025

SDS Number:  
20448-00027

Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

H335 May cause respiratory irritation.  
H361d Suspected of damaging the unborn child.  
H402 Harmful to aquatic life.

### Precautionary statements

#### **Prevention:**

P203 Obtain, read and follow all safety instructions before use.  
P261 Avoid breathing dust.  
P264 + P265 Wash hands thoroughly after handling. Do not touch eyes.  
P271 Use only outdoors or with adequate ventilation.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

#### **Response:**

P304 + P340 + P319 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Get medical help if you feel unwell.  
P305 + P354 + P338 + P317 IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Get medical help.  
P318 IF exposed or concerned, get medical advice.

#### **Storage:**

P405 Store locked up.

#### **Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

### Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (%) w/w)
Raltegravir	871038-72-1	>= 20 - < 25
Cellulose	9004-34-6	>= 20 - < 30
Magnesium stearate	557-04-0	>= 1 - < 5
Ammonium hydroxide	1336-21-6	>= 0.1 - < 0.25

## 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.

When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version  
6.1

Revision Date:  
13.11.2025

SDS Number:  
20448-00027

Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

---

In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Causes serious eye damage. May cause respiratory irritation. Suspected of damaging the unborn child. Contact with dust can cause mechanical irritation or drying of the skin.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

---

## 5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Nitrogen oxides (NO <sub>x</sub> ) Fluorine compounds Metal oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

---

## 6. ACCIDENTAL RELEASE MEASURES

---

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version  
6.1

Revision Date:  
13.11.2025

SDS Number:  
20448-00027

Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air. Add excess liquid to allow the material to enter into solution. Soak up with inert absorbent material. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

## 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Avoid breathing dust. Do not swallow. Do not get in eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version  
6.1

Revision Date:  
13.11.2025

SDS Number:  
20448-00027

Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

	environment.
Conditions for safe storage	: Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.
Materials to avoid	: Do not store with the following product types: Strong oxidizing agents

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Raltegravir	871038-72-1	TWA	1000 (µg/m3) (OEB 1)	Internal
Cellulose	9004-34-6	TWA	10 mg/m3	ACGIH
Magnesium stearate	557-04-0	TWA (Inhal- able particu- late matter)	10 mg/m3	ACGIH
		TWA (Res- pirable par- ticulate mat- ter)	3 mg/m3	ACGIH
Ammonium hydroxide	1336-21-6	TWA	25 ppm 18 mg/m3	IN OEL
		STEL	35 ppm 27 mg/m3	IN OEL
		TWA	25 ppm (Ammonia)	ACGIH
		STEL	35 ppm (Ammonia)	ACGIH

**Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection : Chemical-resistant gloves

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version  
6.1

Revision Date:  
13.11.2025

SDS Number:  
20448-00027

Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

	potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: powder
Colour	: off-white
Odour	: odourless
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available
Relative vapour density	: No data available
Relative density	: No data available
Solubility(ies)	
Water solubility	: No data available

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version 6.1      Revision Date: 13.11.2025      SDS Number: 20448-00027      Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

---

Partition coefficient: n-octanol/water : No data available  
Auto-ignition temperature : No data available  
Decomposition temperature : No data available  
Viscosity  
    Viscosity, kinematic : No data available  
Explosive properties : Not explosive  
Oxidizing properties : The substance or mixture is not classified as oxidizing.  
Molecular weight : No data available  
Particle characteristics  
    Particle size : No data available

---

## 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.  
Chemical stability : Stable under normal conditions.  
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.  
Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.  
Incompatible materials : Oxidizing agents  
Hazardous decomposition products : No hazardous decomposition products are known.

---

## 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation  
    Skin contact  
    Ingestion  
    Eye contact

### Acute toxicity

Not classified based on available information.

### Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg  
    Method: Calculation method

### Components:

#### **Raltegravir:**

Acute oral toxicity : LD50 (Mouse, male and female): > 2,000 mg/kg

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version 6.1      Revision Date: 13.11.2025      SDS Number: 20448-00027      Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

---

### **Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

### **Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

### **Ammonium hydroxide:**

Acute oral toxicity : LD50 (Rat): 350 mg/kg  
Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

### **Skin corrosion/irritation**

Not classified based on available information.

### **Components:**

#### **Raltegravir:**

Species : Rabbit  
Result : No skin irritation

#### **Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

#### **Ammonium hydroxide:**

Species : Rabbit  
Result : Corrosive after 3 minutes to 1 hour of exposure  
Remarks : Based on national or regional regulation.

### **Serious eye damage/eye irritation**

Causes serious eye damage.

### **Components:**

#### **Raltegravir:**

Species : Bovine cornea

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version 6.1      Revision Date: 13.11.2025      SDS Number: 20448-00027      Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

---

Result : Severe irritation

### **Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

### **Ammonium hydroxide:**

Result : Irreversible effects on the eye  
Remarks : Based on skin corrosivity.

### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

### **Components:**

#### **Raltegravir:**

Test Type : Local lymph node assay (LLNA)  
Species : Mouse  
Result : negative

#### **Magnesium stearate:**

Test Type : Maximisation Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative  
Remarks : Based on data from similar materials

### **Germ cell mutagenicity**

Not classified based on available information.

### **Components:**

#### **Raltegravir:**

Genotoxicity in vitro : Test Type: reverse mutation assay  
Result: negative

Test Type: Alkaline elution assay  
Test system: rat hepatocytes  
Result: negative

Test Type: Chromosomal aberration  
Method: OECD Test Guideline 473  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version  
6.1

Revision Date:  
13.11.2025

SDS Number:  
20448-00027

Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

Species: Mouse  
Result: negative

Test Type: Chromosomal aberration  
Method: OECD Test Guideline 475  
Result: negative

### **Cellulose:**

Genotoxicity in vitro

: Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo

: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

### **Magnesium stearate:**

Genotoxicity in vitro

: Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

### **Ammonium hydroxide:**

Genotoxicity in vitro

: Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

### **Carcinogenicity**

Not classified based on available information.

### **Components:**

#### **Raltegravir:**

Species : Mouse, male and female  
Exposure time : 104 weeks  
Result : negative

#### **Cellulose:**

Species : Rat  
Application Route : Ingestion

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version 6.1      Revision Date: 13.11.2025      SDS Number: 20448-00027      Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

---

Exposure time : 72 weeks  
Result : negative

### Reproductive toxicity

Suspected of damaging the unborn child.

#### Components:

##### **Raltegravir:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Application Route: Oral  
General Toxicity - Parent: NOAEL: 600 mg/kg body weight  
Result: negative

Effects on foetal development : Species: Rat  
Application Route: Oral  
General Toxicity Maternal: NOAEL:  $\geq$  600 mg/kg body weight  
Teratogenicity: LOAEL F1: 300 mg/kg body weight  
Symptoms: Skeletal malformations  
Result: positive

Species: Rabbit  
General Toxicity Maternal: NOAEL:  $\geq$  1,000 mg/kg body weight  
Teratogenicity: NOAEL:  $\geq$  1,000 mg/kg body weight  
Result: negative

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

##### **Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

##### **Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version Revision Date: SDS Number: Date of last issue: 09.05.2025  
6.1 13.11.2025 20448-00027 Date of first issue: 09.10.2014

Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

## STOT - single exposure

May cause respiratory irritation.

## **Components:**

## Raltegravir:

Exposure routes	:	Inhalation
Target Organs	:	Respiratory Tract
Assessment	:	May cause respiratory irritation.

## STOT - repeated exposure

Not classified based on available information.

## Repeated dose toxicity

## Components:

## Raltegravir:

Species : Dog  
NOAEL : 90 mg/kg  
Application Route : Oral  
Exposure time : 371 d  
Symptoms : Vomiting

Species	:	Rat
NOAEL	:	30 mg/kg
LOAEL	:	120 mg/kg
Application Route	:	Oral
Exposure time	:	189 d
Target Organs	:	Stomach

Species : Mouse  
NOAEL : 50 mg/kg  
LOAEL : 500 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Target Organs : Stomach

Species	:	Rat
NOAEL	:	50 mg/kg
LOAEL	:	200 mg/kg
Application Route	:	Oral
Exposure time	:	8 Weeks
Target Organs	:	Stomach

## Cellulose:

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version 6.1      Revision Date: 13.11.2025      SDS Number: 20448-00027      Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

---

Application Route : Ingestion  
Exposure time : 90 Days

### **Magnesium stearate:**

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

### **Aspiration toxicity**

Not classified based on available information.

### **Experience with human exposure**

#### **Components:**

#### **Raltegravir:**

Ingestion : Symptoms: Nausea, Diarrhoea, Headache, Fever, Rash, Skin irritation

---

## 12. ECOLOGICAL INFORMATION

### **Ecotoxicity**

#### **Components:**

#### **Raltegravir:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 ( Pseudokirchneriella subcapitata (green algae)): 66 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201

NOEC ( Pseudokirchneriella subcapitata (green algae)): 3.8 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 3 h

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version  
6.1

Revision Date:  
13.11.2025

SDS Number:  
20448-00027

Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 9.3 mg/l  
Exposure time: 33 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 9.5 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211

### Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

### Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 ( Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

NOELR ( Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
Exposure time: 16 h

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version  
6.1

Revision Date:  
13.11.2025

SDS Number:  
20448-00027

Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

Test substance: Water Accommodated Fraction  
Remarks: Based on data from similar materials

### Ammonium hydroxide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.89 mg/l  
Exposure time: 96 h  
Test substance: Neutralised product

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 101 mg/l  
Exposure time: 48 h

M-Factor (Acute aquatic toxicity) : 1

Toxicity to fish (Chronic toxicity) : NOEC: 0.0135 mg/l  
Exposure time: 73 d  
Species: Oncorhynchus mykiss (rainbow trout)  
Test substance: Neutralised product

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.961 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Remarks: Based on data from similar materials

### Persistence and degradability

#### Components:

##### **Raltegravir:**

Biodegradability : Result: rapidly degradable  
Biodegradation: 50 %  
Exposure time: 9 d  
Method: OECD Test Guideline 302B

Stability in water : Hydrolysis: < 10 %(5 d)  
Method: OECD Test Guideline 111

##### **Cellulose:**

Biodegradability : Result: Readily biodegradable.

##### **Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

### Bioaccumulative potential

#### Components:

##### **Raltegravir:**

Partition coefficient: n-octanol/water : log Pow: -0.328

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version  
6.1

Revision Date:  
13.11.2025

SDS Number:  
20448-00027

Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

---

### **Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

### **Mobility in soil**

No data available

### **Other adverse effects**

No data available

---

## 13. DISPOSAL CONSIDERATIONS

### **Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## 14. TRANSPORT INFORMATION

### **International Regulations**

#### **UNRTDG**

Not regulated as a dangerous good

#### **IATA-DGR**

Not regulated as a dangerous good

#### **IMDG-Code**

Not regulated as a dangerous good

### **Transport in bulk according to IMO instruments**

Not applicable for product as supplied.

### **Special precautions for user**

Not applicable

---

## 15. REGULATORY INFORMATION

### **Safety, health and environmental regulations/legislation specific for the substance or mixture**

#### **The components of this product are reported in the following inventories:**

AICS : not determined

CA. DSL : not determined

IECSC : not determined

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version 6.1	Revision Date: 13.11.2025	SDS Number: 20448-00027	Date of last issue: 09.05.2025 Date of first issue: 09.10.2014
----------------	------------------------------	----------------------------	---

### 16. OTHER INFORMATION

Revision Date : 13.11.2025

#### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

#### Full text of other abbreviations

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
IN OEL	: India. Permissible levels of certain chemical substances in work environment.
ACGIH / TWA	: 8-hour, time-weighted average
ACGIH / STEL	: Short-term exposure limit
IN OEL / TWA	: Time-Weighted Average Concentration (TWA) (8 hrs.)
IN OEL / STEL	: Short-term exposure Limit STEL (15 min)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonised System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organisation; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardisation; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organisation for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Raltegravir Pediatric Granules Formulation

Version  
6.1

Revision Date:  
13.11.2025

SDS Number:  
20448-00027

Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

---

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN